Efficacy News and Research

RSS

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Clinical trial of lipase inhibitor for the treatment of obesity

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.

9 Aug 2004

Bush administration is depriving millions access to life-saving generic drugs

AIDS Healthcare Foundation, has commended the World Health Organization (WHO) for their leadership and sincere interest in ensuring the safety of generic HIV/AIDS drugs in the developing world.

6 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Experimental vaccine against ricin

Scientists have developed an experimental vaccine against ricin, a potential biological threat agent, which fully protected mice from aerosol challenge with lethal doses of the toxin.

5 Aug 2004

Atherosclerosis at menopause slowed by diet and exercise

Thickening of artery walls accelerates as women enter menopause, but these signs of the progression of atherosclerosis can be slowed by a lower-fat diet and increased physical activity, according to a new study in the Aug. 4, 2004, issue of the Journal of the American College of Cardiology.

5 Aug 2004

Half of the complications and deaths due to in-hospital DVT can be prevented with once daily dalteparin

Current research supports the use of blood-thinners to help acutely ill, hospitalized patients minimize the risk of death from a pulmonary embolism (PE) and its precursor deep vein thrombosis (DVT).

3 Aug 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

One-third of U.S. adults use some form of alternative medicine

More than one-third of U.S. adults use some form of alternative medicine such as herbal supplements and other therapies, showed in a nationwide survey by NIH's National Center for Complementary and Alternative Medicine published in May 2004.

2 Aug 2004

Study evaluated the ability of vitamin E and Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease

Researchers in the neurology department in the University of Arizona College of Medicine in Tucson participated in a study that evaluated the ability of vitamin E and donepezil hydrochloride, marketed as Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease.

2 Aug 2004

European recommended approval of Remicade for treatment of psoriatic arthritis

Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products has issued a positive opinion recommending approval of expanded labeling for REMICADE(R) (infliximab), in combination with methotrexate, for treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to disease modifying anti- rheumatic drugs (DMARDs).

2 Aug 2004

Clinical benefit for moderate-to-severe plaque psoriasis patients treated with Raptiva for 30 months

Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.

2 Aug 2004

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

Warning for counterfeit drugs simvastatin and carisoprodol recently imported from Mexico

The U.S. Food and Drug Administration has issued a public warning regarding counterfeit versions of the drugs simvastatin and carisoprodol that have recently been imported from Mexico to the U.S.

31 Jul 2004

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.

29 Jul 2004

Transplanted cells are capable of surviving in the brain of immunosuppressed stroked rats

Human neural stem cells proprietary to StemCells, Inc. have been used in a Stanford University study in a preclinical stroke model.

29 Jul 2004

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

A new study reveals the highest efficacy rates ever reported among patients co-infected with hepatitis C and HIV treated with pegylated interferon and ribavirin.

28 Jul 2004

Wide range of professions use heuristics to assist them with complex decision making, doctors are no exception

Correct treatment of serious medical conditions can be a matter of life and death for patients, so the quality of the processes by which doctors reach their decisions is critical.

27 Jul 2004

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

Efficacy News and Research

New biotech alliance to focus on diseases of nerve injury and pain

Clinical trial of lipase inhibitor for the treatment of obesity

Bush administration is depriving millions access to life-saving generic drugs

Approval of Cymbalta for treatment of major depressive disorder

Experimental vaccine against ricin

Atherosclerosis at menopause slowed by diet and exercise

Half of the complications and deaths due to in-hospital DVT can be prevented with once daily dalteparin

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

One-third of U.S. adults use some form of alternative medicine

Study evaluated the ability of vitamin E and Aricept, to delay the progression of mild cognitive impairment to Alzheimer's disease

European recommended approval of Remicade for treatment of psoriatic arthritis

Clinical benefit for moderate-to-severe plaque psoriasis patients treated with Raptiva for 30 months

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Warning for counterfeit drugs simvastatin and carisoprodol recently imported from Mexico

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Transplanted cells are capable of surviving in the brain of immunosuppressed stroked rats

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

Wide range of professions use heuristics to assist them with complex decision making, doctors are no exception

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News